Function preservation in stage III squamous laryngeal carcinoma: Results with an induction chemotherapy protocol
- 1 August 1995
- journal article
- clinical trial
- Published by Wiley in The Laryngoscope
- Vol. 105 (8) , 822-826
- https://doi.org/10.1288/00005537-199508000-00010
Abstract
Until recently, standard treatment for stage III laryngeal carcinoma (LC) was total laryngectomy and radiotherapy. Recent data suggest that induction chemotherapy (ICH) plays a role in preserving function in advanced head and neck cancer. No reports to date prospectively evaluate ICH exclusively in stage III LC. The authors designed a sequential phase II trial to assess if ICH allowed a conservative treatment in this disease. The objective of the first part of the study was to rule out a complete response rate with ICH below 30% with P≤.05. ICH protocol consisted of three courses of cisplatin 100 mg/M2 on day 1 and 5‐fluorouracil 5000 mg/M2 continuous infusion over 120 hours. Radiotherapy was administered to patients who attained a complete response (CR). Functional surgery (FS) was planned for patients with partial response. A total laryngectomy followed by radiotherapy was performed when FS was not feasible. Fifty‐two previously untreated patients (all males) with squamous stage III LC were diagnosed in our institution, and 46 were entered in the ICH trial. After 9 patients were included, data showed 7 (78%) CR, ruling out a CR rate of less than 30%. After ICH, a CR was achieved in 29 (63%) of 46 patients. At the end of treatment, 35 patients (76%) had a functioning larynx. With a median follow‐up of 3 years, larynx function was preserved in 26 (57%) of 46 patients and in 64% of survivors. Four‐year actuarial larynx function preservation, overall survival, and disease‐free survival were 55%, 77%, and 67%, respectively. Karnofsky performance score over 80% was the only significant prognostic factor in overall survival (94% at 4 years) and disease‐free survival (78% at 4 years). In conclusion, the authors believe that ICH followed by response‐related second treatment is safe and effective in preserving laryngeal function in stage in LC. There is no evidence of worsening survival.Keywords
This publication has 13 references indexed in Scilit:
- Overview of Combined Modality Therapies for Head and Neck CancerJNCI Journal of the National Cancer Institute, 1993
- Stage T3 squamous cell carcinoma of the glottic larynx: A comparison of laryngectomy and irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal CancerNew England Journal of Medicine, 1991
- Twice-a-day radiation therapy for supraglottic carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 1986
- PLANNED PREOPERATIVE RADIATION THERAPY VS. DEFINITIVE RADIOTHERAPY FOR ADVANCED LARYNGEAL CARCINOMAThe Laryngoscope, 1984
- T3 glottic cancer: Options and consequences of the optionsThe Laryngoscope, 1984
- Speech and SurvivalNew England Journal of Medicine, 1981
- Management of advanced glottic cancer a 10 year review of the Toronto experienceInternational Journal of Radiation Oncology*Biology*Physics, 1979
- Conservation surgery for epidermoid carcinoma of the marginal area (Aryepiglottic fold extension)The Laryngoscope, 1975
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972